Physician profile
Arsalan Khan
NPI 1396984068
$4,421.23
in general payments reported to CMS, 2019-2025
43 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $765 · 2021: $811 · 2022: $676 · 2023: $564 · 2024: $741 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $589.15 | 2019-2023 | |
| Abbott Laboratories | $507.92 | 2019-2025 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit, Amplatzer Amulet |
| Astrazeneca Pharmaceuticals LP | $269.11 | 2019-2024 | Farxiga, Breztri |
| Corcept Therapeutics | $255.27 | 2021-2024 | Korlym |
| Lilly USA, LLC | $250.45 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.45 | 2019-2025 | Jardiance |
| Medicure Pharma INC. | $215.60 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $184.18 | 2020-2025 | |
| Boston Scientific Corporation | $154.49 | 2019-2023 | |
| Novo Nordisk INC | $147.51 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $146.26 | 2020-2025 | Repatha, Repatha |
| Heartflow, INC. | $136.72 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $122.22 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $93.68 | 2019-2023 | Seglentis, Livalo |
| Azurity Pharmaceuticals, INC. | $89.50 | 2023 | Edarbi, Edarbyclor |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $88.93 | 2021-2022 | |
| Pfizer INC. | $83.73 | 2023-2025 | |
| Arbor Pharmaceuticals, INC. | $71.76 | 2019-2022 | |
| Edwards Lifesciences Corporation | $66.23 | 2023-2025 | Sapien 3 Ultra Resilia |
| Glaxosmithkline, LLC. | $63.72 | 2022-2024 | Arexvy, Fluarix Quadrivalent, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $59.74 | 2020-2025 | Camzyos |
| Cvrx, INC. | $51.19 | 2022-2024 | Barostim Neo System |
| Shield Therapeutics INC | $46.50 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $44.56 | 2021-2023 | Kristalose |
| Phathom Pharmaceuticals, INC. | $42.34 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $40.65 | 2023-2024 | Cologuard Collection Kit |
| Cleerly, INC. | $39.79 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Kiniksa Pharmaceuticals International, Plc | $30.55 | 2024 | Arcalyst |
| Abbvie INC. | $29.83 | 2022-2023 | |
| Otter Pharmaceuticals, LLC | $24.99 | 2025 | Sympazan |
| Preventice Services, LLC | $24.77 | 2021 | |
| Dexcom, INC. | $22.73 | 2021 | |
| Scpharmaceuticals INC. | $21.00 | 2024 | |
| Myocardial Solutions, INC. | $20.45 | 2021 | |
| Irhythm Technologies, INC. | $19.68 | 2023 | Zio Xt Patch |
| Medtronic Vascular, INC. | $19.19 | 2019 | |
| Medtronic, INC. | $17.83 | 2025 | Inceptiv |
| Astellas Pharma US INC | $17.66 | 2019 | |
| Redhill Biopharma INC. | $17.51 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.04 | 2019 | |
| Itamar Medical INC | $13.64 | 2021 | |
| Althera Pharmaceuticals LLC | $13.49 | 2021 | |
| Seqirus USA INC | $13.22 | 2024 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arsalan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.